Passage BIO, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Passage BIO, Inc. (PASG), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PASG insiders buying or selling?
In the last 12 months, Passage BIO, Inc. insiders reported 1 open-market purchase ($206.1K) and 2 sales ($113.2K) — net buying of $92.9K. Since March 2020, Trabud has recorded 58 Form 4 filings for PASG: 32 buys ($53.7M) and 26 sells ($1.4M).
Source: SEC EDGAR Form 4
Key Statistics (March 2020 – Jun 29, 2026)
Total Form 4 filings
58
SEC EDGAR
Insider filers
22
Insider buys (32)
$53.7M
Insider sells (26)
$1.4M
Insider sentiment
Net buyingNet insider flow of $52.3M in net buying since March 2020, and $92.9K in net buying over the last 12 months.
Recent PASG insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Lynx1 Capital Management LP | 10% Owner | Purchase | 50.1K | $4.12 | $206.1K | SEC ↗ |
| Jan 12, 2026 | William Chou | PRESIDENT AND CEO | Sale | 4.1K | $18.44 | $75.2K | SEC ↗ |
| Jan 12, 2026 | Kathleen Borthwick | CFO | Sale | 2.1K | $18.44 | $38.0K | SEC ↗ |
| Sep 16, 2025 | Lynx1 Capital Management LP | 10% Owner | Purchase | 32.0K | $6.99 | $223.7K | SEC ↗ |
| Jul 24, 2025 | Lynx1 Capital Management LP | 10% Owner | Purchase | 128.8K | $5.70 | $733.8K | SEC ↗ |
| Jun 26, 2025 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 583.7K | $0.34 | $197.2K | SEC ↗ |
| Apr 24, 2025 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 235.6K | $0.33 | $78.7K | SEC ↗ |
| Apr 17, 2025 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 149.1K | $0.33 | $49.7K | SEC ↗ |
| Feb 12, 2025 | Kathleen Borthwick | CFO | Sale | 3.2K | $0.53 | $1.7K | SEC ↗ |
| Jan 14, 2025 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 223.2K | $0.64 | $142.2K | SEC ↗ |
| Jan 8, 2025 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 147.0K | $0.70 | $103.3K | SEC ↗ |
| Dec 31, 2024 | Lynx1 Capital Management LP | 10% Owner | Purchase | 373.6K | $0.65 | $241.0K | SEC ↗ |
| Dec 26, 2024 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 230.3K | $0.60 | $138.2K | SEC ↗ |
| Dec 11, 2024 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 62.3K | $0.83 | $52.0K | SEC ↗ |
| Dec 7, 2024 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 97.1K | $0.80 | $77.3K | SEC ↗ |
| Nov 27, 2024 | Lynx1 Capital Management LP | 10% Owner | Purchase | 456.4K | $0.62 | $284.5K | SEC ↗ |
| Sep 23, 2024 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 39.3K | $0.71 | $27.9K | SEC ↗ |
| Sep 18, 2024 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 200.1K | $0.73 | $146.7K | SEC ↗ |
| Feb 14, 2024 | Kathleen Borthwick | SVP, INTERIM CFO | Sale | 1.5K | $0.97 | $1.4K | SEC ↗ |
| Feb 14, 2024 | Mark S Forman | CHIEF MEDICAL OFFICER | Sale | 1.6K | $0.97 | $1.6K | SEC ↗ |
| Jan 3, 2024 | Mark S Forman | Chief Medical Officer | Sale | 15.8K | $0.91 | $14.4K | SEC ↗ |
| Jan 3, 2024 | Kathleen Borthwick | SVP, Interim CFO | Sale | 10.7K | $0.91 | $9.7K | SEC ↗ |
| Jan 3, 2024 | Edgar B. Cale | GC & Corporate Secretary | Sale | 15.8K | $0.91 | $14.4K | SEC ↗ |
| Aug 1, 2023 | Simona King | Chief Financial Officer | Sale | 11.5K | $0.88 | $10.1K | SEC ↗ |
| Jun 29, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Purchase | 1.2M | $0.84 | $1.0M | SEC ↗ |
Showing the 25 most recent of 58 Form 4 filings for Passage BIO, Inc..
Most active PASG insiders
- ORBIMED ADVISORS LLC17 filings
- Lynx1 Capital Management LP5 filings
- Kathleen Borthwick4 filings
- Alexandros Fotopoulos3 filings
- Bruce A Goldsmith3 filings
Ask anything about PASG insider activity
Use Trabud's AI agent to query Passage BIO, Inc.'s Form 4 history in plain English — "Show me PASG CEO purchases this year" or compare it against any other ticker.
Open the AI agentPASG insider trading FAQ
Are Passage BIO, Inc. insiders buying or selling?
In the last 12 months, Passage BIO, Inc. insiders reported 1 open-market purchase ($206.1K) and 2 sales ($113.2K) — net buying of $92.9K. Since March 2020, Trabud has recorded 58 Form 4 filings for PASG: 32 buys ($53.7M) and 26 sells ($1.4M). Over the full record that is net buying of $52.3M.
How many insiders trade PASG stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Passage BIO, Inc.. The most recent filing was accepted on Jun 29, 2026.
Where does Trabud get PASG insider trading data?
All PASG insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.